The choice of delivery platform for inhaled drug products is contingent on API-related factors, as well as the development stage of the product.
Tim Gardner
Advertisement
Tim Gardner is director, manufacturing and NPI, Vectura.
Articles by Tim Gardner
Advertisement
Latest Updated Articles
Integrated Approach Facilitates Inhalation Drug DevelopmentAugust 1st 2021
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Signs Point to FDA Shelving Priority Voucher Pilot, Stalling Fast-Track Drug Reviews
2
France Remains One of Europe’s Leading Biotech Funding Hubs
3
CPHI Milan Future Leader Award Winner: Pauline van der Wijst-Janssen
4
The Impact of Excipients on Continuous Manufacturing and the Risk of Nitrites
5